A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459,Administered to Patients With Stargardt's Macular Degeneration
Phase of Trial: Phase I/II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs SAR 422459 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions; First in man
- Sponsors Sanofi
- 26 Sep 2019 Status changed from recruiting to discontinued.
- 10 Apr 2019 Planned number of patients changed from 46 to 41.
- 10 Apr 2019 Planned End Date changed from 1 Feb 2020 to 3 Jun 2019.